Industry updates and clinical trial data at the upcoming 2025 ARVO Annual Meeting

The Eye Care Network will be onsite from 4-8 May for the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Salt Lake City, Utah. Image credit: ©f11photo – stock.adobe.com

The 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting will take place from 4-8 May, 2025, in Salt Lake City, Utah. Ahead of this exciting meeting, several companies have announced that data from clinical trials will be shared at this event.

As researchers prepare for their presentations, the Eye Care Network is highlighting some of the scheduled sessions that will share important research findings from around the globe.

Note: The following list of presentations is in alphabetical order by company. This list will be updated as more information becomes available.

Ashvattha Therapeutics

Jeff Cleland, PhD, CEO of Ashvattha Therapeutics, will present a poster entitled “Subcutaneous Migaldendranib Reduces Anti-VEGF Treatment Burden: A Unique Therapeutic Platform to Treat Retinal Vascular Disease” during the poster session on Wednesday, 7 May, 2025, from 2:00-3:45pm MT.

This poster will highlight Phase 2 results for migaldendranib (MGB), Ashvattha’s investigational subcutaneous treatment for wet age-related macular degeneration (wet AMD) and diabetic macular oedema (DMO). It was previously announced that the phase 2 clinical data demonstrated that MGB administration lowered production of subretinal fluid, reducing or eliminating the need for intravitreal anti-VEGF treatment in both the study eye and fellow eye in wet AMD and DMO subjects with bilateral disease.¹

Clearside Biomedical

Six abstracts related to Clearside’s suprachoroidal drug delivery platform have been accepted for presentation at the 2025 ARVO meeting.² These presentations are as follows:

• Top Line Results from ODYSSEY: A Phase 2b Study of Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-related Macular Degeneration
  • Presented by Robert Wang on Thursday, 8 May, 2025, from 3:00 pm - 3:15 pm MT.
• Suprachoroidal CLS-AX (Axitinib Injectable Suspension) Offers Durability, Safety, and Therapeutic Potential for Neovascular Age-Related Macular Degeneration (nAMD) Patients: Preclinical and Clinical Corroboration
  • Posterboard number A0125 presented by Viral Kansara, PhD on Wednesday, 7 May, 2025, from 10:15 am - 12:00 pm MT
• The Evolving Role of Suprachoroidal Drug Delivery in Macular Diseases: A Decade-Long Literature Review
  • Posterboard number B0517 presented by Victor Chong, MD, MBA on Monday, 5 May, 2025, from 8:30 am - 10:15 am MT
• Validation of Suprachoroidal Injection Training Program with a Synthetic Eye Model
  • Posterboard number B0415 presented by Chen-rei Wan on Thursday, 8 May, 2025, from 8:00 am - 9:45 am MT
• Dispensability Analysis of Suspension Formulations
  • Posterboard number B0515 presented by Darrin Rountree, MS on 5 May, 2025, from 8:30 am - 10:15 am MT
• Novel Deep Learning Algorithm for Suprachoroidal Space Segmentation and Measurement in Optical Coherence Tomography
  • Posterboard number A0229 presented by Oluwagbemisola Aderibigbe on 4 May, 2025, from 1:00 pm - 2:45 pm MT

EyePoint Pharmaceuticals

Data from EyePoint has been accepted for presentation at the upcoming 2025 ARVO Annual Meeting. The company plans to showcase its clinical trial datasets for is phase 2 VERONA trial and phase 2 DAVIO 2 trial, which across multiple indications saw continued safety and efficacy, as well as the program’s de-risked study designs that reflect real-world patient populations.³

Eyestem Research

Eyestem has recently shared that all patients across three cohorts in the company’s phase 1 trials of its investigational drug, Eyecyte-RPE, in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) were dosed without any serious adverse events. The first six patients showed an average 14.9-letter gain in ETDRS vision tests within 4–6 months, with early signs of disease reversal seen in some retinal scans. Data from this trial will be presented at the ARVO meeting.⁴

Iolyx Therapeutics

The company will present new developments and updates on its lead candidate, ILYX-002, for immune-driven dry eye disease (DED) from a recent Phase 2 clinical trial, ILYX-002-201. The presentation will take place during the Dry Eye: Clinical Aspects II session on 8 May, 2025, 8:00 am – 9:45 am MST. Dr Mark Hinds, principal investigator for the ILYX-002-201 trial, will be the presenter on the company’s behalf.⁵

Opus Genetics

Three abstracts on the company’s investigational gene therapy candidates have been accepted for presentation at the ARVO 2025 Meeting. The abstracts feature 12-month data from the first three adult patients in the ongoing Phase 1/2 trial of OPGx-LCA5, as well as preclinical results on OPGx-MERTK and OPGx-RDH12.⁶

• Evaluation of MERTK gene therapy in RCS rats following a single bilateral subretinal injection
  • Presented by Mayur Choudhary, PhD, on 8 May, 2025, from 11:45 am to 1:30 pm MT.
• Evaluation of ocular tolerability of OPGx-RDH12 by subretinal delivery in cynomolgus primates
  • Presented by Ash Jayagopal, PhD, on 5 May, 2025, from 8:30 am to 10:15 am MT
• LYNX-1 Phase 3 trial of the safety and efficacy of phentolamine ophthalmic solution for the treatment of reduced mesopic low contrast vision: A subset analysis of keratorefractive subjects
  • Presented by Kostas Charizanis, PhD on 4 May, 2025 from 8:00 am to 9:45 am MT

TMR Pharma N.V.

TME Pharma N.V. and the Singapore Eye Research Institute (SERI) will present a poster highlighting data from preclinical studies performed with mNOX-E36 by SERI at the ARVO Annual Meeting. Preclinical data show that mNOX-E36 is as efficacious as standard-of-care mitomycin C (MMC) at attenuating postoperative inflammation and scarring (fibrosis) following glaucoma filtration surgery (GFS).⁷

The poster will be titled “Inhibition of MCP-1 with mNOX-E36 reduces scarring in an experimental murine model of glaucoma filtration surgery” and will be posterboard number A0418. It will be presented by Professor Tina Wong on 6 May, 2025, from 8:30 am – 10:15 am MT.⁷

Reference:

1. Ashvattha Therapeutics to Present at ARVO, Retina World Congress, and AOS Annual Meeting. Ashvattha Therapeutics. April 15, 2025. Accessed April 16, 2025. https://www.globenewswire.com/news-release/2025/04/15/3061682/0/en/Ashvattha-Therapeutics-to-Present-at-ARVO-Retina-World-Congress-and-AOS-Annual-Meeting.html

2. Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting. Clearside Biomedical. March 24, 2025. Accessed April 16, 2025. https://www.globenewswire.com/news-release/2025/03/24/3047721/0/en/Clearside-Biomedical-Announces-Six-Abstracts-Accepted-for-Presentation-at-Association-for-Research-in-Vision-and-Ophthalmology-ARVO-2025-Meeting.html

3. EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments. EyePoint Pharmaceuticals. March 5, 2025. Accessed April 16, 2025. https://www.globenewswire.com/news-release/2025/03/05/3037277/0/en/EyePoint-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Highlights-Recent-Corporate-Developments.html

4. Eyestem’s Eyecyte-RPE™ Trial Shows Vision Rescue for Geographic Atrophy Patients. Eyestem Research. April 15, 2025. Accessed April 16, 2025. https://www.businesswire.com/news/home/20250414346272/en/Eyestems-Eyecyte-RPE-Trial-Shows-Vision-Rescue-for-Geographic-Atrophy-Patients

5. Iolyx Therapeutics to Present at Multiple Upcoming Ophthalmology Conferences. Iolyx Therapeutics, Inc. March 12, 2025. Accessed April 16, 2025. https://www.globenewswire.com/news-release/2025/03/12/3041356/0/en/Iolyx-Therapeutics-to-Present-at-Multiple-Upcoming-Ophthalmology-Conferences.html

6. Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting. Opus Genetics. March 5, 2025. Accessed April 16, 2025. https://www.globenewswire.com/news-release/2025/03/05/3037375/0/en/Opus-Genetics-Announces-Presentations-at-Association-for-Research-in-Vision-and-Ophthalmology-ARVO-2025-Meeting.html

7. TME Pharma Announces Filing of Patents for Use of CCL2 Inhibitor NOX-E36 in Ophthalmology and Presentation at ARVO 2025 of Preclinical Data Showing Benefit in Glaucoma Filtration Surgery. TMR Pharma N.V. March 13, 2025. Accessed April 16, 2025. https://www.businesswire.com/news/home/20250313839845/en/TME-Pharma-Announces-Filing-of-Patents-for-Use-of-CCL2-Inhibitor-NOX-E36-in-Ophthalmology-and-Presentation-at-ARVO-2025-of-Preclinical-Data-Showing-Benefit-in-Glaucoma-Filtration-Surgery